Core Laboratories (NYSE:CLB) Price Target Raised to $15.00 at Citigroup

Core Laboratories (NYSE:CLB) had its price target raised by Citigroup from $14.00 to $15.00 in a research report report published on Thursday,Benzinga reports. The brokerage currently has a sell rating on the oil and gas company’s stock.

Separately, StockNews.com raised shares of Core Laboratories from a “sell” rating to a “hold” rating in a report on Thursday, November 7th. Two equities research analysts have rated the stock with a sell rating and three have issued a hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $17.25.

Core Laboratories Stock Down 4.4 %

Shares of NYSE:CLB opened at $16.13 on Thursday. The stock has a market capitalization of $755.13 million, a price-to-earnings ratio of 24.43, a price-to-earnings-growth ratio of 0.99 and a beta of 2.38. Core Laboratories has a 1-year low of $13.82 and a 1-year high of $25.13. The company’s fifty day moving average is $17.96 and its two-hundred day moving average is $18.79. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.71 and a current ratio of 2.32.

Core Laboratories (NYSE:CLB) last issued its earnings results on Wednesday, January 29th. The oil and gas company reported $0.23 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.23. Core Laboratories had a net margin of 5.99% and a return on equity of 16.24%. Equities analysts anticipate that Core Laboratories will post 0.96 EPS for the current year.

Core Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 3rd. Investors of record on Monday, February 10th will be issued a $0.01 dividend. The ex-dividend date of this dividend is Monday, February 10th. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.25%. Core Laboratories’s dividend payout ratio (DPR) is presently 6.06%.

Hedge Funds Weigh In On Core Laboratories

A number of institutional investors and hedge funds have recently bought and sold shares of CLB. GSA Capital Partners LLP bought a new position in Core Laboratories in the 3rd quarter valued at about $434,000. Oppenheimer Asset Management Inc. grew its position in Core Laboratories by 18.9% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 64,582 shares of the oil and gas company’s stock valued at $1,197,000 after buying an additional 10,272 shares in the last quarter. Royce & Associates LP grew its position in Core Laboratories by 9.0% in the 3rd quarter. Royce & Associates LP now owns 1,021,121 shares of the oil and gas company’s stock valued at $18,921,000 after buying an additional 84,022 shares in the last quarter. Connable Office Inc. grew its position in Core Laboratories by 18.1% in the 3rd quarter. Connable Office Inc. now owns 16,793 shares of the oil and gas company’s stock valued at $311,000 after buying an additional 2,569 shares in the last quarter. Finally, Integrated Investment Consultants LLC grew its position in Core Laboratories by 19.9% in the 3rd quarter. Integrated Investment Consultants LLC now owns 16,290 shares of the oil and gas company’s stock valued at $302,000 after buying an additional 2,709 shares in the last quarter. Institutional investors own 97.81% of the company’s stock.

Core Laboratories Company Profile

Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.